ADIAL PHARMACEUTICALS, INC. - 10-Q Filing
Adial Pharmaceuticals filed its Q1 2026 Form 10-Q reporting a net loss of $2.02 million for the three months ended March 31, 2026, compared to a net loss of $2.23 million in the same period last year. The company reported total operating expenses of $2.00 million (vs. $2.27 million YoY), driven by research and development costs ($432,530) and general/administrative expenses ($1.57 million). Cash and cash equivalents decreased to $4.58 million from $5.88 million as of December 31, 2025.
Tickers: $ADIL